Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...